| Motionhealth | |
|
1426 Fillmore St 206 San Francisco CA 94115-5236 | |
| (415) 346-7871 | |
| Not Available |
| Full Name | Motionhealth |
|---|---|
| Speciality | Clinic/center - Primary Care |
| Location | 1426 Fillmore St, San Francisco, California |
| Authorized Official Name and Position | Ronald Johnson (CFO) |
| Authorized Official Contact | 7042674912 |
| Accepts Medicare Insurance | This clinic does not participate in Medicare Program. |
| Mailing Address | Practice Location Address |
|---|---|
| Motionhealth 405 14th St Suite 712 Oakland CA 94612-2715 Ph: (704) 267-4912 | Motionhealth 1426 Fillmore St 206 San Francisco CA 94115-5236 Ph: (415) 346-7871 |
| NPI Number | 1134593031 |
|---|---|
| Provider Enumeration Date | 11/17/2015 |
| Last Update Date | 11/17/2015 |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1134593031 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 261QP2300X | Clinic/center - Primary Care | (* (Not Available)) | Primary |
News Archive
Oncothyreon Inc. today announced enrollment of the first patient in a Phase 2 trial of PX-866 in patients with recurrent or metastatic castration-resistant prostate cancer. PX-866 is a small molecule compound designed to inhibit the activity of phosphatidylinositol-3-kinase (PI-3K), a component of an important cell survival signaling pathway.
Approximately one year after successful treatment with cytotoxic chemotherapy and radiotherapy, patients with advanced Small Cell Lung Cancer (SCLC), which primarily affects heavy smokers, generally relapse with recurrence of tumours that are resistant to further chemotherapy.
Discovery Laboratories, Inc., a specialty biotechnology company dedicated to advancing a new standard in respiratory critical care, today announced that the United States Food and Drug Administration (FDA) has approved SURFAXIN (lucinactant) for the prevention of Respiratory Distress Syndrome (RDS) in premature infants at high risk for RDS.
Undocumented migrants are an especially vulnerable group with regard to their health status, living conditions, and barriers to access to health care and social welfare.
Scientists from the University of Würzburg have synthesized a complex sugar molecule which specifically binds to the tumor protein Galectin-1. This could help to recognize tumors at an early stage and to combat them in a targeted manner.
› Verified 6 days ago
Richard Joseph Md Pc Primary Care Clinic Medicare: Medicare Enrolled Practice Location: 548 Market St # 50727, San Francisco, CA 94104 Phone: 415-851-3224 | |
James Y.greenberg, Md, A Professional Corporation Primary Care Clinic Medicare: Medicare Enrolled Practice Location: 2299 Post St Ste 205, San Francisco, CA 94115 Phone: 415-474-7955 Fax: 415-292-0718 | |
Inpatient Services Of California, Inc., A Medical Corporation Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 3555 Cesar Chavez St, San Francisco, CA 94110 Phone: 415-641-6401 | |
Jew & Jew Medical Associates Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 919 Clay St, San Francisco, CA 94108 Phone: 415-982-4011 Fax: 415-982-6291 | |
Hampton Health Ltd Primary Care Clinic Medicare: Medicare Enrolled Practice Location: 1700 California St, Ste. 470, San Francisco, CA 94109 Phone: 415-202-9990 Fax: 415-843-0548 | |
North East Medical Services-leland Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 82 Leland Avenue, San Francisco, CA 94134 Phone: 415-391-9686 Fax: 415-333-9067 | |
Mission Area Health Associates Primary Care Clinic Medicare: Medicare Enrolled Practice Location: 1580 Valencia St Ste 506, San Francisco, CA 94110 Phone: 415-852-4080 Fax: 415-431-3178 |